每周使用两性霉素 B 脂质体初治慢性肺曲霉菌病：乌干达的病例报告

IF 1.6 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Medical Mycology Case Reports Pub Date : 2024-08-27 DOI:10.1016/j.mmcr.2024.100666

Winnie Kibone , Felix Bongomin , David W. Denning , David B. Meya

{"title":"每周使用两性霉素 B 脂质体初治慢性肺曲霉菌病：乌干达的病例报告","authors":"Winnie Kibone , Felix Bongomin , David W. Denning , David B. Meya","doi":"10.1016/j.mmcr.2024.100666","DOIUrl":null,"url":null,"abstract":"<div><p>Chronic pulmonary aspergillosis (CPA) treatment in Africa remains unexplored. We present a 23-year-old Ugandan male, previously treated thrice for pulmonary tuberculosis, developing CPA. Imaging showed lung fibrosis, bronchiectasis, and a fungal ball. He received weekly 600mg (10mg/kg) of liposomal amphotericin B for six weeks, leading to marked clinical improvement. Weekly liposomal amphotericin B may be a viable treatment option for CPA in resource-limited settings.</p></div>","PeriodicalId":51724,"journal":{"name":"Medical Mycology Case Reports","volume":"46 ","pages":"Article 100666"},"PeriodicalIF":1.6000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S221175392400040X/pdfft?md5=869eeb1f4620398c42e0bdd62fda606c&pid=1-s2.0-S221175392400040X-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Primary treatment of chronic pulmonary aspergillosis with weekly liposomal amphotericin B: A case report from Uganda\",\"authors\":\"Winnie Kibone , Felix Bongomin , David W. Denning , David B. Meya\",\"doi\":\"10.1016/j.mmcr.2024.100666\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Chronic pulmonary aspergillosis (CPA) treatment in Africa remains unexplored. We present a 23-year-old Ugandan male, previously treated thrice for pulmonary tuberculosis, developing CPA. Imaging showed lung fibrosis, bronchiectasis, and a fungal ball. He received weekly 600mg (10mg/kg) of liposomal amphotericin B for six weeks, leading to marked clinical improvement. Weekly liposomal amphotericin B may be a viable treatment option for CPA in resource-limited settings.</p></div>\",\"PeriodicalId\":51724,\"journal\":{\"name\":\"Medical Mycology Case Reports\",\"volume\":\"46 \",\"pages\":\"Article 100666\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-08-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S221175392400040X/pdfft?md5=869eeb1f4620398c42e0bdd62fda606c&pid=1-s2.0-S221175392400040X-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Medical Mycology Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S221175392400040X\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical Mycology Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S221175392400040X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

摘要

慢性肺曲霉菌病（CPA）在非洲的治疗仍有待探索。我们为您介绍一名 23 岁的乌干达男性患者，他曾因肺结核接受过三次治疗，后来患上了慢性肺曲霉菌病。影像学检查显示肺部纤维化、支气管扩张和真菌球。他每周接受 600 毫克（10 毫克/千克）两性霉素 B 脂质体治疗六周，临床症状明显改善。在资源有限的情况下，每周服用两性霉素 B 脂质体可能是治疗 CPA 的一种可行方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Primary treatment of chronic pulmonary aspergillosis with weekly liposomal amphotericin B: A case report from Uganda

Chronic pulmonary aspergillosis (CPA) treatment in Africa remains unexplored. We present a 23-year-old Ugandan male, previously treated thrice for pulmonary tuberculosis, developing CPA. Imaging showed lung fibrosis, bronchiectasis, and a fungal ball. He received weekly 600mg (10mg/kg) of liposomal amphotericin B for six weeks, leading to marked clinical improvement. Weekly liposomal amphotericin B may be a viable treatment option for CPA in resource-limited settings.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Medical Mycology Case Reports MEDICINE, RESEARCH & EXPERIMENTAL-

CiteScore

4.00

自引率

0.00%

发文量

审稿时长

47 days